Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorine F 18 + GEH121224
- Development stage
- Discontinued
- Lead developer
- GE Healthcare
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Fluorine F 18 + GEH121224 is a radioconjugate composed of GEH121224, a ligand that specifically targets human epidermal growth factor receptor 2 (HER2; also known as ErbB2), and is labeled with the positron-emitting radioisotope fluorine F 18. The compound is designed for use as a positron emission tomography (PET) radiotracer for non-invasive imaging of HER2 expression in patients, primarily with advanced or metastatic HER2-positive breast cancer. The radiotracer allows clinicians to assess HER2 positivity and tumor burden, aiding in diagnosis and therapy planning. The use of the F 18 isotope allows for high-resolution PET imaging to detect and quantify HER2 status in real time[7][1][2][3]. Currently, the drug is in early-stage clinical trials to evaluate its safety, radiation dosimetry, biodistribution, pharmacokinetics, and optimal imaging protocols in the indicated patient population[2][3][8].
- Other names
- fluorine F 18 GEH121224
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on fluorine F 18 + GEH121224.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorine F 18 + GEH121224.